Prevalence and antibiotic sensitivity patterns of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in pneumonia patients at Ngoerah Hospital from 2020 to 2022
Main Article Content
Keywords
Klebsiella pneumoniae, Extended-Spectrum Beta-Lactamase, Antibiotic Sensitivity, Antibiotic Resistance, ESBL-producing Klebsiella pneumoniae
Abstract
Background: Pneumonia remains a major global cause of mortality, with Klebsiella pneumoniae recognized as a significant pathogen. The emergence of antibiotic resistance, particularly due to Extended-Spectrum Beta-Lactamase (ESBL) production by K. pneumoniae, complicates treatment efforts. This study aimed to determine the prevalence of ESBL-producing K. pneumoniae in pneumonia patients and assess its antibiotic sensitivity profile.
Methods: A descriptive cross-sectional study was conducted retrospectively using secondary data from VITEK 2 Compact (bioMérieux) laboratory results on sputum samples collected from pneumonia patients at Ngoerah Hospital from 2020 to 2022. A total of 515 samples met the inclusion criteria out of 1,350 tested.
Results: ESBL-producing K. pneumoniae was identified in 305 isolates (59.2%), with yearly prevalence rates of 63% in 2020, 52% in 2021, and 61% in 2022. Most patients were male (66.6%), aged 60 years or older (40%), and treated in non-ICU settings (69.2%), with expectorated sputum as the most common specimen type (63%). Antibiotic sensitivity testing revealed high susceptibility of ESBL-producing isolates to ertapenem (100%), meropenem (100%), amikacin (93%), and tigecycline (81%).
Conclusion: ESBL-producing K. pneumoniae accounted for over half of pneumonia cases, with fluctuating prevalence across the study period. The infection predominantly affected older male patients treated in non-ICU wards. Despite resistance to many beta-lactam antibiotics, high sensitivity to carbapenems and other specific agents highlights their continued relevance in treatment. Surveillance of antibiotic resistance patterns remains essential for effective clinical management.
References
2. Aliberti S, Dela Cruz CS, Amati F, Sotgiu G, Restrepo MI. Community-acquired pneumonia. Lancet. 2021;398(10303):906-919. doi:10.1016/S0140-6736(21)00630-9.
3. Wang G, Zhao G, Chao X, Xie L, Wang H. The Characteristic of Virulence, Biofilm and Antibiotic Resistance of Klebsiella pneumoniae. Int J Environ Res Public Health. 2020;17(17):6728. doi:10.3390/ijerph17176278.
4. Centers for Disease Control and Prevention. National Infection & Death Estimates for Antimicrobial Resistance [Internet]. Atlanta (GA): CDC; 2021 [Cited: 10th January 2025]. [Available from: https://www.cdc.gov/antimicrobial-resistance/data-research/facts-stats/index.html]
5. Ikuta KS, Swetschinski LR, Robles Aguilar G, Sharara F, Mestrovic T, Gray AP, et al. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2022;400(10369):2221–2248. doi:10.1016/S0140-6736(22)02185-7.
6. Ramadhani CH. Hubungan antara Hospital-Acquired Pneumonia yang disebabkan oleh Extended-Spectrum Beta-Lactamase producing Klebsiella pneumoniae dengan Clinical Outcome Pasien di RSUD Dr. Saiful Anwar Malang [Skripsi]. Fakultas Kedokteran Universitas Brawijaya. 2019.
7. Suhartono S, Hayati Z, Mahdani W, Andini F. Distribution of ESBL-producing and non-ESBL-producing Klebsiella pneumoniae isolated from sputum specimens in the Zainoel Abidin General Hospital, Banda Aceh, Indonesia. Biodiversitas. 2024;25(7):3247–3254. doi:10.13057/biodiv/d250746.
8. Muztika SA, Nasrul E, Alia E. Prevalensi dan Pola Sensitivitas Antibiotik Klebsiella pneumoniae dan Escherichia coli Penghasil Extended Spectrum Beta Laktamase di RSUP Dr. M Djamil Padang. J Kesehat Andalas. 2020;9(2):189-194. doi:10.25077/jka.v9i2.1272
9. Zhang J, Zhou K, Zheng B, Zhao L, Shen P, Ji J, et al. High Prevalence of ESBL-Producing Klebsiella pneumoniae Causing Community-Onset Infections in China. Front Microbiol. 2016;7:1830. doi:10.3389/fmicb.2016.01830.
10. Siriphap A, Kitti T, Khuekankaew A, Boonlao C, Thephinlap C, Thepmalee C, et al. High prevalence of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates: A 5-year retrospective study at a Tertiary Hospital in Northern Thailand. Front Cell Infect Microbiol. 2022;12:955774. doi:10.3389/fcimb.2022.955774
11. Salawudeen A, Raji YE, Jibo GG, Desa MNM, Neoh H, Masri SN, et al. Epidemiology of multidrug-resistant Klebsiella pneumoniae infection in clinical setting in South-Eastern Asia: a systematic review and meta-analysis. Antimicrob Resist Infect Control. 2023;12(1):142. doi:10.1186/s13756-023-01346-5.
12. Dias SP, Brouwer MC, van de Beek D. Sex and Gender Differences in Bacterial Infections. Infect Immun. 2022;90(10):e0028322. doi:10.1128/iai.00283-22.
13. Rahma PC, Widyantara AB, Nailufar Y. Gambaran Pola Kepekaan Antibiotik Bakteri Klebsiella pneumoniae Penghasil Extended Spectrum Beta Laktamase di ICU Rumah Sakit PKU Muhammadiyah Yogyakarta. J Kesehat Tambusai. 2024;5(3):7829–7836. doi:10.31004/jkt.v5i3.33216.
14. Ku NS, Kim YC, Kim MH, Song JE, Oh DH, Ahn JY, et al. Risk factors for 28-day mortality in elderly patients with extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae bacteremia. Arch Gerontol Geriatr. 2014;58(1):105-109. doi:10.1016/j.archger.2013.07.002.
15. Sinanjung K, Aman AT, Nirwati H. Extended spectrum beta lactamase (ESBL)-producing Klebsiella pneumoniae clinical isolates and its susceptibility pattern to antibiotics at Dr. Soeradji Tirtonegoro General Hospital Klaten, Central Java. Journal of the Medical Sciences (Berkala Ilmu Kedokteran). 2020;52(01):17–27. doi:10.19106/JMedSci005201202003.
16. Lestari DC, Karuniawati A, Saharman YR, Sedono R. Patients Infected by Extended-Spectrum Beta-Lactamase Producing Klebsiella Pneumoniae: Risk Factors and Outcomes. eJournal Kedokteran Indonesia. 2020;8(1):46-51. doi:10.23886/ejki.8.10427.
17. Moustafa NM, Mahmoud FM, Khamsin NWB, Almomen F, Alali M, Abosbaih M, et al. Antimicrobial Susceptibility of Klebsiella pneumoniae Isolated from Intensive and Non-intensive Care Units Patients: A One-year Retrospective Study in a Tertiary Healthcare Hospital, Saudi Arabia. J Pure Appl Microbiol. 2023;17(4):2453–2466. doi:10.22207/JPAM.17.4.43.
18. Ahmad Q, Sabrina T, Diba MF, Amalia E, Putra RA. Gambaran Infeksi Klebsiella pneumoniae Penghasil Extended-Spectrum β-Lactamase (ESBL) Pada Pasien COVID-19 di RSUP Dr. Mohammad Hoesin Periode Januari 2021- Juni 2021. Jambi Med J. 2022;10(2):186–198.
19. Chaisaeng S, Phetburom N, Kasemsiri P, Putthanachote N, Wangnadee N, Boueroy P, et al. Phenotypic and Genotypic Profiles of Extended-Spectrum Beta-Lactamase-Producing Multidrug-Resistant Klebsiella pneumoniae in Northeastern Thailand. Antibiotics. 2024;13(10):917. doi:10.3390/antibiotics13100917.
20. Abrami M, Biasin A, Tescione F, Tierno D, Dapas B, Carbone A, et al. Mucus Structure, Viscoelastic Properties, and Composition in Chronic Respiratory Diseases. Int J Mol Sci. 2024;25(3):1933. doi:10.3390/ijms25031933.
21. Elmawati EW, Pratiwi DIN, Muthmainah N, Biworo A. Antibiotic Susceptibility Pattern of Extended-Spectrum Beta-Lactamase-Producing Klebsiella Pneumoniae and Escherichia Coli. Indones J Clin Pathol Med Lab. 2021;27(3):282–288. doi: 10.24293/ijcpml.v27i3.1634.
22. Enyinnaya SO, Iregbu KC, Uwaezuoke NS, Abdullahi N, Lawson SD. Molecular Detection and Antibiotic Susceptibility Profile of ESBL-producing Klebsiella pneumoniae Isolates in a Central Nigerian Tertiary Hospital. Greener Journal of Medical Sciences. 2021;11(2):181–186.
23. Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA. Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. Clin Infect Dis. 2024:ciae403. doi:10.1093/cid/ciae403